Table 2.

Univariate and multivariate analysis

	Univariate (PFS)		Univariate (OS)		Multivariate (PFS)		Multivariate (OS)
	HR (95 % CI)	p value	HR (95 % CI)	p value	HR (95 % CI)	p value	HR (95 % CI)	p value
Group
MMP3 and pIGF1R−	Reference		Reference		Reference		Reference
MMP3 or pIGF1R+	1.39 (0.71–2.72)	0.34	1.10 (0.52–2.17)	0.95	1.53 (0.76–3.06)	0.23	1.67 (0.77–3.65)	0.20
Albumin >median	0.73 (0.44–1.23)	0.24	0.82 (0.47–1.44)	0.49
Leucocytes >median	1.16 (0.73–1.85)	0.53	1.50 (0.90–2.49)	0.12
LDH >median	1.36 (0.84–2.21)	0.21	1.50 (0.89–2.55)	0.13
Age	0.99 (0.97–1.00)	0.33	0.99 (0.98–1.01)	0.51
Kit mutation
Exon 11/13	0.46 (0.28–0.76)	0.021	0.71 (0.41–1.21)	0.21	0.57 (0.33–0.97)	0.037
Other	Reference		Reference
ECOG
PS 0	Reference		Reference		Reference		Reference
PS 1	1.13 (0.67–1.8)	0.65	1.17 (0.66–2.07)	0.59	1.74 (0.99–3.07)	0.055	2.00 (1.08–3.67)	0.026
PS > 1	1.64 (0.73–3.68)	0.23	2.05 (0.88–4.76)	0.095	4.45 (1.85–10.76)	0.0009	5.25 (2.08–13.26)	0.0005
Female	1.02 (0.64–1.63)	0.92	1.01 (0.61–1.67)	0.96
Primary site
Stomach	1.61 (1.00–2.59)	0.050	1.36 (0.82–2.27)	0.24
Others	Reference		Reference
Extension of disease								Ta
1 metastatic organ	Reference		Reference		Reference		Reference
2 or more metastatic organs	2.59 (1.52–4.42)	0.0005	2.56 (1.46–4.52)	0.0011	1.84 (1.03–3.27)	0.039	1.93 (1.03–3.62)	0.041
Surgery primary tumor
Yes	Reference		Reference
No	1.19 (0.51–2.75)		0.75 (0.27–2.08)	0.59			0.26 (0.09–0.76)	0.014
Disease-free interval		0.69
<24 months	13.4 (6.93–25.77)	<0.0001	6.61 (3.72–11.79)	<0.0001	18.87 (8.54–41.73)	<0.0001	16.73 (7.97–35.13)	<0.0001
≥24 months	Reference		Reference		Reference		Reference